DBVT News and Press, DBV Technologies S.A. From 07/31/23

2023-07-31 20:02:16 ET DBV Technologies S.A. (DBVT) Q2 2023 Earnings Call July 31, 2023 17:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer ...

2023-07-31 16:29:01 ET DBV Technologies press release ( NASDAQ: DBVT ): Q2  GAAP EPS of -$0.26. Revenue of $2.3M (+53.3% Y/Y). For further details see: DBV Technologies GAAP EPS of -$0.26, revenue of $2.3M

Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Stud ies and Reports Second Quarter and Half-Year 2023 Financial Results R eceived feedback...

Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical com...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR ...

Montrouge, France, June 8, 2023 DBV Technologies to Participate i n Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming particip...

2023-05-16 08:30:17 ET Modular Medical ( MODD ) -24% . Eloxx Pharmaceuticals ELOX -22% after Q1 earning release . LM Funding America ( LMFA ) -18% . Horizon Therapeutics Public Limited Company HZNP -18% reports FTC preparing suit to block Amgen de...

2023-05-11 15:31:03 ET Shares of DBV Technologies (NASDAQ: DBVT) were up 14.5% early Thursday afternoon after the New England Journal of Medicine published phase 3 data on DBV's trial on its peanut allergy therapy for children aged one to three. The biotech company's shares ...

2023-05-10 18:18:51 ET Gainers: Purple Innovation ( PRPL ) +25% . DBV Technologies ( DBVT ) +24% . KLX Energy Services Holdings ( KLXE ) +23% . Digimarc Corporation ( DMRC ) +18% . Applovin Corporation ( APP ) +13% . Losers...